[2]
Xu, J.; Khan, A.; Fu, M.; Wang, R.; Ji, J.; Zhai, G. Cell-penetrating peptide: A means of breaking through the physiological barriers of different tissues and organs. Jour. of control. Rele., 2019, 309, 106-124.
[31]
Smith, J.; Jenkins, R. Genetic alterations in adult diffuse glioma:
Occurrence, significance, and prognostic implications. Front. in
biosci., 2000, 5, D213-D231.
[41]
Erreni, M.; Solinas, G.; Brescia, P.; Osti, D.; Zunino, F.; Colombo, P.; Destro, A.; Roncalli, M.; Mantovani, A.; Draghi, R.; Levi, D.; Rodriguez, Y; Baena, R.; Gaetani, P.; Pelicci, G.; Allavena, P. Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1. Eur. J. of Cancer (Oxford, England : 1990),, 2010, 46(18), 3383-3392.
[44]
Bloch, O.; Crane, C.; Kaur, R.; Safaee, M.; Rutkowski, M.; Parsa, A. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin. Cancer Res., 2013, 19(12), 3165-3175.
[45]
Okada, H.; Butterfield, L.; Hamilton, R.; Hoji, A.; Sakaki, M.; Ahn, B.; Kohanbash, G.; Drappatz, J.; Engh, J.; Amankulor, N.; Lively, M.; Chan, M.; Salazar, A.; Shaw, E.; Potter, D.; Lieberman, F. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin. Cancer Res., 2015, 21(2), 286-294.
[81]
Zhou, Y.; Peng, Z.; Seven, E.; Leblanc, R. Crossing the blood-brain barrier with nanoparticles. J. of Control. Rel, 2018, 270, 290-303.
[92]
Zaro, J.L.; Shen, W. Cationic and amphipathic cell-penetrating peptides (CPPs): Their structures and in vivo studies in drug delivery. Front. Chem. Eng. China, 2015, 9(4), 407-427.
[106]
Kim, J.; Shin, D.; Kim, J. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells. J. of Control. Rel, 2018, 269, 245-257.
[107]
Drappatz, J.; Brenner, A.; Wong, E.; Eichler, A.; Schiff, D.; Groves, M.; Mikkelsen, T.; Rosenfeld, S.; Sarantopoulos, J.; Meyers, C.; Fielding, R.; Elian, K.; Wang, X.; Lawrence, B.; Shing, M.; Kelsey, S.; Castaigne, J.; Wen, P. Phase I study of GRN1005 in recurrent malignant glioma. Clin. Cancer Res., 2013, 19(6), 1567-1576.
[112]
Bogdanowich-Knipp, S.; Chakrabarti, S.; Williams, T.; Dillman, R.; Siahaan, T. Solution stability of linear vs cyclic RGD peptides. The J. of Peptide Res, 1999, 53(5), 530-541.
[116]
Zhou, M.; Jiang, N.; Fan, J.; Fu, S.; Luo, H.; Su, P.; Zhang, M.; Shi, H.; Zeng, J.; Huang, Y.; Li, Y.; Shen, H.; Zhang, A.; Li, R.HK (R)-modified pH-sensitive self-assembled nanoparticles delivering small interfering RNA targeting hepatoma-derived growth factor for malignant glioma treatment. J. of Control. Rel, 2019, 310, 24-35.
[133]
Alves, I. D.; Carré, M.; Montero, M. P.; Castano, S.; Lecomte, S.; Marquant, R.; Lecorché, P.; Burlina, F.; Schatz, C.; Sagan, S. A proapoptotic peptide conjugated to penetratin selectively inhibits tumor cell growth. BBA – biomembranes, 2014, 1838(8), 2087-2098.,
[138]
Berges, R.; Balzeau, J.; Peterson, A.; Eyer, J. A tubulin binding peptide targets glioma cells disrupting their microtubules, blocking migration, and inducing apoptosis. Mol. Ther., 2012, 20(7), 1367-1377.
[147]
Platten, M.; Schilling, D.; Bunse, T.; Sahm, F.; Hueckelhoven, A.; Schenkel, I.; Stevanovic, S.; Schmitt, A.; Laumann, M.; Steinbach, J. P. .A mutation-specific peptide vaccine targeting IDH1R132H in
patients with newly diagnosed malignant astrocytomas: A first-inman
multicenter phase I clinical trial of the German Neurooncology
Working Group (NOA-16). J. of Clin. Oncol., 2016, 34(15_suppl),
TPS2082-TPS2082.,
[159]
Keskin, D.B.; Anandappa, A.J.; Sun, J.; Tirosh, I.; Mathewson, N.D.; Li, S.; Oliveira, G.; Giobbie-Hurder, A.; Felt, K.; Gjini, E.; Shukla, S.A.; Hu, Z.; Li, L.; Le, P.M.; Allesøe, R.L.; Richman, A.R.; Kowalczyk, M.S.; Abdelrahman, S.; Geduldig, J.E.; Charbonneau, S.; Pelton, K.; Iorgulescu, J.B.; Elagina, L.; Zhang, W.; Olive, O.; McCluskey, C.; Olsen, L.R.; Stevens, J.; Lane, W.J.; Salazar, A.M.; Daley, H.; Wen, P.Y.; Chiocca, E.A.; Harden, M.; Lennon, N.J.; Gabriel, S.; Getz, G.; Lander, E.S.; Regev, A.; Ritz, J.; Neuberg, D.; Rodig, S.J.; Ligon, K.L.; Suvà, M.L.; Wucherpfennig, K.W.; Hacohen, N.; Fritsch, E.F.; Livak, K.J.; Ott, P.A.; Wu, C.J.; Reardon, D.A. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.
Nature, 2019,
565(7738), 234-239.
[
http://dx.doi.org/10.1038/s41586-018-0792-9] [PMID:
30568305]
[160]
Hilf, N.; Kuttruff-Coqui, S.; Frenzel, K.; Bukur, V.; Stevanović, S.; Gouttefangeas, C.; Platten, M.; Tabatabai, G.; Dutoit, V.; van der Burg, S.H.; Thor Straten, P.; Martínez-Ricarte, F.; Ponsati, B.; Okada, H.; Lassen, U.; Admon, A.; Ottensmeier, C.H.; Ulges, A.; Kreiter, S.; von Deimling, A.; Skardelly, M.; Migliorini, D.; Kroep, J.R.; Idorn, M.; Rodon, J.; Piró, J.; Poulsen, H.S.; Shraibman, B.; McCann, K.; Mendrzyk, R.; Löwer, M.; Stieglbauer, M.; Britten, C.M.; Capper, D.; Welters, M.J.P.; Sahuquillo, J.; Kiesel, K.; Derhovanessian, E.; Rusch, E.; Bunse, L.; Song, C.; Heesch, S.; Wagner, C.; Kemmer-Brück, A.; Ludwig, J.; Castle, J.C.; Schoor, O.; Tadmor, A.D.; Green, E.; Fritsche, J.; Meyer, M.; Pawlowski, N.; Dorner, S.; Hoffgaard, F.; Rössler, B.; Maurer, D.; Weinschenk, T.; Reinhardt, C.; Huber, C.; Rammensee, H.G.; Singh-Jasuja, H.; Sahin, U.; Dietrich, P.Y.; Wick, W. Actively personalized vaccination trial for newly diagnosed glioblastoma.
Nature, 2019,
565(7738), 240-245.
[
http://dx.doi.org/10.1038/s41586-018-0810-y] [PMID:
30568303]